article thumbnail

Akero’s New MASH Drug Data: Longer Treatment Leads to More Liver Benefit

MedCity News

The latest Akero data build on six-month results reported in 2022. Akero Therapeutics’ preliminary Phase 2b data show that treatment with its MASH drug, efruxifermin, continued to distance itself from a placebo measured at nearly two years of treatment.

Leads 312
article thumbnail

LTS Lohmann leads investment in needle-free delivery specialist

Fierce Pharma

LTS Lohmann leads investment in needle-free delivery specialist. Tue, 11/29/2022 - 10:21.

Leads 188
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Physician Opinions on Burnout in 2022 – Blog

InCrowd

In November of 2022, InCrowd surveyed 500 US physicians to track burnout. In 2022, reports showed that physician burnout had risen to frightening levels. Down from 45% in 2021, only 30% of respondents in 2022 find their profession extremely rewarding. The] health system is hard to navigate and [has] too many admin hurdles.”

article thumbnail

A realistic view of healthcare in 2022

World of DTC Marketing

6ix: HCPs and insurers continue to ignore the most significant health crisis in this country – Obesity is out of control, and it’s leading to a myriad of health issues. The post A realistic view of healthcare in 2022. I expect more companies to integrate more health monitors into wearable devices.

article thumbnail

Marketing-Led COVID-19 Growth Strategies: 2022 and Beyond

This is your chance to create unprecedented brand awareness, bring in the best leads sales has ever seen, and play an instrumental role in generating new and existing business revenue. Define and agree on “qualified leads”. In this eBook, you’ll discover what it takes to develop and drive a successful marketing-led growth strategy.

article thumbnail

No Surprises Act Leads to Thousands More Disputes and Delays than Gov’t Expected

MedCity News

When the federal government enacted the No Surprises Act to lessen payment disputes between a patient or a health insurance plan and a provider, the government projected 22,000 disputes in 2022. However, between just April and September there were more than 90,000 disputes filed. .

Leads 246
article thumbnail

Gilead’s $285M Confidence Vote for Next-Gen Cancer Med & New Cell Therapy Tech

MedCity News

Gilead Sciences is increasing its stake in partner Arcellx and expanding the cell therapy alliance the companies started in 2022. The deal expands the lead partnered program to more cancers and gives Gilead a chance at another Arcellx cell therapy candidate made with different technology.

Leads 306